By searching for GRIN2A as a cancer driver gene (i.e., only mutations, fusions, and copy number alterations which are driver events, as defined in OncoPrint), it was found that genetic alterations with the putative driver function are identified in 0.5% and 0.6% of all tumors with melanoma prevalence in the GENIE and TCGA projects, respectively (Figure 5 and Figure 6). This evidence concerns the gene GRIN2A and cancer.